Skaggs School of Pharmacy and Pharmaceutical Sciences, ⊥Department of NanoEngineering, §Department of Chemistry, and ∥Department of Radiology, University of California at San Diego , La Jolla, California 92093, United States.
Mol Pharm. 2012 Jul 2;9(7):1911-8. doi: 10.1021/mp2005998. Epub 2012 Jun 13.
Macromolecular contrast agents have the potential to assist magnetic resonance imaging (MRI) due to their high relaxivity, but are not clinically useful because of toxicity due to poor clearance. We have prepared a biodegradable ketal-based polymer contrast agent which is designed to degrade rapidly at physiological pH by hydrolysis, facilitating renal clearance. In vitro, the agent degraded more rapidly at lower pH, with complete fragmentation after 24 h at pH 7.4. In vitro relaxivity measurements showed a direct correlation between molecular weight and relaxivity. We compared our polymer contrast agent with commercially available Magnevist in vivo by MRI imaging, as well as measuring the Gd concentration in blood. Our results show that our polymer contrast agent gives a higher contrast and intensity in the same organs and areas as Magnevist and is cleared from the blood at a similar rate. We aim to improve our polymer contrast agent design to develop it for use as a MRI contrast agent, and explore its use as a platform for other imaging modalities.
高分子对比剂由于其高弛豫率,有潜力辅助磁共振成像(MRI),但由于清除率差导致毒性,因此在临床上没有用处。我们已经制备了一种可生物降解的缩酮基聚合物对比剂,设计为在生理 pH 值下通过水解快速降解,促进肾脏清除。体外实验表明,该试剂在较低 pH 值下降解更快,在 pH 值为 7.4 时 24 小时后完全碎裂。体外弛豫率测量结果表明,分子量与弛豫率之间存在直接相关性。我们通过 MRI 成像以及测量血液中的 Gd 浓度,将我们的聚合物对比剂与市售的 Magnevist 进行了体内比较。我们的结果表明,我们的聚合物对比剂在与 Magnevist 相同的器官和区域提供更高的对比度和强度,并且以相似的速率从血液中清除。我们旨在改进我们的聚合物对比剂设计,将其开发为 MRI 对比剂,并探索其在其他成像模式中的应用。